Table 5 Univariate and multivariate analyses showing that Pin1/RhoA/RhoC co- overexpression could serve as an independent prognostic factor for recurrence of HCC patients
Relative risk (95% confidence interval | P-value | |
|---|---|---|
Univariate analysis | ||
Age, year (> 55 versus ≤55) | 1.350 (0.802–2.270) | 0.258 |
Gender (male versus female) | 1.041 (0.576–1.881) | 0.894 |
HBsAg (positive versus negative) | 0.820 (0.451–1.489) | 0.513 |
Cirrhosis (yes versus no) | 0.921 (0.565–1.503) | 0.743 |
Tumor Size (> 5 versus ≤5) | 1.576 (0.950–2.614) | 0.078 |
TNM stage (III to IV versus I to II) | 4.857 (2.841–8.303) | <0.001 |
Pin1 + RhoA/RhoC co-overexpression (yes versus no) | 2.804 (1.686–4.663) | <0.001 |
Multivariate analysis | ||
Age, year (> 55 versus ≤55) | 0.749 (0.3359–1.564) | 0.442 |
Gender (male versus female) | 0.838 (0.433–1.622) | 0.600 |
HBsAg (positive versus negative) | 0.958 (0.495–1.854) | 0.899 |
Cirrhosis (yes versus no) | 0.890 (0.498–1.590) | 0.694 |
Tumor Size (> 5 versus ≤5) | 1.268 (0.692–2.326) | 0.442 |
TNM stage (III to IV versus I to II) | 3.453 (1.814–6.573) | <0.001 |
Pin1 + RhoA/RhoC co-overexpression (yes versus no) | 2.159 (1.078–4.325) | <0.001 |